Raredr

Treatment for MPS I - A Patient's Perspective

Erika Thiel
Published Online: February 16, 2017


Erika Thiel of GeneSpotlight talks about her rare disease - Mucopolysaccharidosis (MPS) 1 - and  the limitations of the currently approved enzyme replacement therapy [Aldurazyme (laronidase)].

Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$